SEC Info - Acasti Pharma Inc. - ‘6-K’ for 1/13/20

SEC Info℠

Home

Help

Please Sign In

Acasti Pharma Inc. – ‘6-K’ for 1/13/20

On: Monday, 1/13/20, at 6:21am ET · For: 1/13/20 · Accession #: 1171843-20-177 · File #: 1-35776

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/13/20  Acasti Pharma Inc.                6-K         1/13/20    2:56K                                    Globenewswire Inc./FA

Current Report by a Foreign Issuer — Form 6-K — Rule 13a-16 / 15d-16
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Current Report by a Foreign Issuer                  HTML      7K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     19K

‘6-K’ — Current Report by a Foreign Issuer

This is an HTML Document rendered as filed. [ Alternative Formats ]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January 2020

Commission File Number: 001-35776

ACASTI PHARMA INC.
(Translation of registrant's name into English)

545 Promende du Centropolis
Suite 100
Laval, Québec
Canada H7T 0A3
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ] Form 40-F [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Explanatory Note

This Report on Form 6-K including the exhibits hereto shall be deemed to be incorporated by reference into Acasti Pharma Inc.’s registration statements on Form S-8 (No. 333-191383 and No. 333-227476) and on Form F-3 (No. 333-220755, No. 333-233063 and No. 333-223464) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ACASTI PHARMA INC.


Date: January 13, 2020	By:	/s/ *Jan D'Alvise*
		Name: Jan D'Alvise
		Title: Chief Executive Officer

EXHIBIT INDEX

Exhibit Number		Description

99.1		Press Release dated January 13, 2020

Dates Referenced Herein and Documents Incorporated by Reference

This ‘6-K’ Filing	Date	Other Filings

Filed on / For Period end:	1/13/20	None on these Dates
		List all Filings

↑Top

Filing Submission 0001171843-20-000177 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)